GRAMD1A and neoplasm: In addition, subcutaneous xenograft tumor models using DLD1 cells harboring mutant (G13D/−), wild-type (+/–) or both KRAS alleles (G13D/+) further indicated that GRAMD1A knock-down showed more pronounced effect on tumor volume and weight in KRAS mutant tumors (Fig. S10A–D).